Zobrazeno 1 - 10
of 153
pro vyhledávání: '"Ross C. Smith"'
Publikováno v:
Cancer Medicine, Vol 11, Iss 2, Pp 492-506 (2022)
Abstract Background and Aims Cancer‐associated stroma (CAS) is emerging as a key determinant of metastasis in colorectal cancer (CRC); however, little is known about CAS in colorectal liver metastases (CRLM). This study aimed to validate the progno
Externí odkaz:
https://doaj.org/article/b1b601d2d51c41e9a2c42d7d41e1e117
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 18, Iss 7, Pp 425-435 (2016)
BACKGROUND: Extensive cross talk exists between PI3K/Akt/mTOR and mitogen-activated protein kinase (MAPK) pathways, and both are upregulated in pancreatic ductal adenocarcinoma (PDAC). Our previous study suggested that epidermal growth factor recepto
Externí odkaz:
https://doaj.org/article/0293d56686f54accaad482542a29b03c
Publikováno v:
Cancers, Vol 3, Iss 2, Pp 1821-1843 (2011)
Evidence for the efficacy of targeted alpha therapy for the control of pancreatic cancer in preclinical models is reviewed. Results are given for in vitro pancreatic cancer cells and clusters and micro-metastatic cancer lesions in vivo. Two complemen
Externí odkaz:
https://doaj.org/article/7fd0b5d2741842438c8616788797f7fb
Autor:
Ross C. Smith, Robert C. Baxter, Lyndsay Peters, Anthony J. Gill, Thomas J. Hugh, Jaswinder S. Samra, Nick Pavlakis, Sohel M. Julovi, Aiqun Xue, Matthew H. Wong
Purpose: PI3K–Akt is overexpressed in 50% to 70% of pancreatic ductal adenocarcinoma (PDAC). The hypothesis of this study is that PI3K and EGFR coinhibition may be effective in PDAC with upregulated PI3K–Akt signaling.Experimental Design: Multipl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7078f1d6724d8d188180ac5f712599a4
https://doi.org/10.1158/1078-0432.c.6524699
https://doi.org/10.1158/1078-0432.c.6524699
Autor:
Ross C. Smith, Robert C. Baxter, Lyndsay Peters, Anthony J. Gill, Thomas J. Hugh, Jaswinder S. Samra, Nick Pavlakis, Sohel M. Julovi, Aiqun Xue, Matthew H. Wong
Figure S5: Effect of single and dual blockade (DB) on cell proliferation (A, B) 3D contour maps for inhibition by ERL+AEW (A) and ERL+BYL (B). Synergy index (SI) was calculated by non-linear regression (PROC NLIN) using the Bliss synergy/antagonism f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5362093a86bf9ce15c7c3defde169fdf
https://doi.org/10.1158/1078-0432.22461143.v1
https://doi.org/10.1158/1078-0432.22461143.v1
Autor:
John F. Timms, Stephen P. Pereira, Eithne Costello, Usha Menon, Ian J. Jacobs, Ross C. Smith, Alexey Zaikin, Anne Dawnay, Richard Gunu, Oleg Blyuss, Stephane Camuzeaux, Evangelia-Ourania Fourkala, Sophia Apostolidou, Aleksandra Gentry-Maharaj, Claire Jenkinson, Neomal S. Sandanayake, Darragh P. O'Brien
PDF file - 206K, Table S1 Numbers of test positive cases and controls using CA19-9 37 U/mL and CA125 30 U/mL cut-offs Figure S1 Scatter plots showing distribution of CA19-9, CA125, CEACAM1 and REG3A levels against time to diagnosis for discovery set.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19db5b9040eeb056a80b0dfe16f82fe0
https://doi.org/10.1158/1078-0432.22455122
https://doi.org/10.1158/1078-0432.22455122
Autor:
Ross C. Smith, Robert C. Baxter, Lyndsay Peters, Anthony J. Gill, Thomas J. Hugh, Jaswinder S. Samra, Nick Pavlakis, Sohel M. Julovi, Aiqun Xue, Matthew H. Wong
Table S1: IC50 values for inhibition of proliferation of (A) 5 PDAC cell lines and (B) 2 derived erlotinib-resistant (ER) cell lines, in response to inhibitors of EGFR (erlotinib, gefitinib), IGF1R (NVP-AEW541), MEK (PD-98059), PI3K (LY-294002), PI3K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::430e8492ed31bc58f775819b252b7a4f
https://doi.org/10.1158/1078-0432.22461125.v1
https://doi.org/10.1158/1078-0432.22461125.v1
Autor:
Ross C. Smith, Robert C. Baxter, Lyndsay Peters, Anthony J. Gill, Thomas J. Hugh, Jaswinder S. Samra, Nick Pavlakis, Sohel M. Julovi, Aiqun Xue, Matthew H. Wong
Supplementary Methods and Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c3f9636ac3dc8d3ea1e81e547684f66
https://doi.org/10.1158/1078-0432.22461128
https://doi.org/10.1158/1078-0432.22461128
Autor:
John F. Timms, Stephen P. Pereira, Eithne Costello, Usha Menon, Ian J. Jacobs, Ross C. Smith, Alexey Zaikin, Anne Dawnay, Richard Gunu, Oleg Blyuss, Stephane Camuzeaux, Evangelia-Ourania Fourkala, Sophia Apostolidou, Aleksandra Gentry-Maharaj, Claire Jenkinson, Neomal S. Sandanayake, Darragh P. O'Brien
Purpose: Biomarkers for the early detection of pancreatic cancer are urgently needed. The primary objective of this study was to evaluate whether increased levels of serum CA19-9, CA125, CEACAM1, and REG3A are present before clinical presentation of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1512461bdf64c7da1ec1e1214d924d43
https://doi.org/10.1158/1078-0432.c.6522926.v1
https://doi.org/10.1158/1078-0432.c.6522926.v1
Autor:
Sohel M. Julovi, Nicholas Proschogo, Leo Phillips, Aiqun Xue, Sarah F. Smith, Anthony J. Gill, Jerikho C. Bulanadi, Ross C. Smith, Thomas J. Hugh, Minoo J. Moghaddam, Kerry-Anne Rye, Xiaojuan Gong
Publikováno v:
Cancer Letters. 495:112-122
We hypothesised that synthetic HDL nanoparticles carrying a gemcitabine prodrug and apolipoprotein A-II (sHDLGemA2) would target scavenger receptor-B1 (SR-B1) to preferentially and safely deliver gemcitabine into pancreatic ductal adenocarcinoma (PDA